Skip to content

Sergio Rutella


School of Science & Technology


Sergio Rutella is a licensed haematologist and Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre. His academic career has been predicated on the bench-to-bedside-to-bench paradigm in Haematology. Over the last 25 years, Professor Rutella has been engaged in clinical and translational research focusing on immunotherapy approaches to improve the outcome of haematological malignancies, with an emphasis on antibody-based therapeutics and haematopoietic stem cell transplantation. He has an extensive track record of leading studies that involve a strong correlative component and collaborating with other investigators both basic and clinical. At Nottingham Trent University, Professor Rutella’s research program focuses on visualising the state of cancer-immune interactions in individual patients and on biomarker discovery, with the aim to implement the design of rational immunotherapy approaches, to guide treatment choices and to minimise toxicity.

During his academic career, Professor Sergio Rutella has authored and co-authored 216 full-length, peer-reviewed publications (H-index=56; i10-index=171; times cited>11,000) and 13 book chapters, and has secured £4,606,278 of research funding as principal investigator/co-investigator. His teaching contributions are made to Bachelors and Masters projects on the BIOL40111 MSc Research Project module, the BIOL40102 "Research Methods and Bioethics" module, and the BIOL33171 "Immunology and Virology" module.

Career overview

2020 (Oct): Interim Director, John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom

2020 (Jan): Director, Centre for Health, Ageing and Understanding Disease (CHAUD), School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom

2016-present: Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom

2017: Fellowship by Published Works; Royal College of Pathologists, United Kingdom

2017: General Medical Council (GMC) Specialist Registration (Haematology) with a Licence to Practice, United Kingdom

2014-2016: Executive Director of Clinical Research, Sidra Medical and Research Center, Doha, Qatar

2012-2014: Chair and Head of Clinical Service, Immunohaematology and Transfusion Medicine, Bambino Gesù Children’s Hospital, Rome, Italy

2011: Consultant Haematologist, Department of Paediatric Haematology/Oncology and Transfusion Medicine, Bambino Gesù Children’s Hospital, Rome, Italy

2000-2011: Assistant Professor of Haematology and Consultant Haematologist, Agostino Gemelli University Polyclinic, Catholic University Medical School, Rome, Italy

2001 (1997-2001): PhD in Experimental Haematology, Catholic University Medical School, Rome, Italy

1997 (1993-1997): Post-graduate specialisation (Certificate of Completion of Training) in Haematology (summa cum laude), Catholic University Medical School, Rome, Italy

1993 (1986-1993): Degree in Medicine and Surgery (MD; summa cum laude), Catholic University Medical School, Rome, Italy

Honours and international recognition:

2019: Vice Chancellor's Outstanding Researcher Award (Established Researcher), Nottingham Trent University, United Kingdom

2011: Junior Faculty Award, American Association of Immunologists, Bethesda, MD, USA

2006: Junior Faculty Award, American Association of Immunologists, Bethesda, MD, USA

2005: European Commission’s Marie Curie Actions Scholarship, ESH-EBMT Eurocord

2003: Showell-Pfizer Award, American Association of Immunologists, Bethesda, MD, USA

2002: Showell-Pfizer Award, American Association of Immunologists, Bethesda, MD, USA

Research areas

Areas of clinical research interest for Professor Rutella’s team include:

Novel immunotherapy approaches for haematological malignancies.

Elements of this research work focus on the challenges encountered with the effective treatment of acute myeloid leukaemia (AML) and combine systems biology approaches (targeted immune gene expression and micro-RNA profiling, spatially-resolved digital protein profiling-immunohistochemistry, multi-parameter flow cytometry, data mining and bioinformatics expertise) to:

-Discover gene signatures that are reflective of general immune status and predictive of anti-cancer immune potential;

-Assess immune cell infiltration and the expression of immune checkpoint molecules;

-Identify ‘actionable’ molecular pathways that can predict patient outcome and therefore assist the tailoring and improve the effectiveness of therapeutic interventions.

IFN-gamma-mediated tumour immune evasion and response to immunotherapy.

Pro-tumorigenic activities of IFN-gamma have recently emerged depending on the context, intensity and durability of IFN-gamma signalling. The research team is studying whether T-cell infiltration and IFN-gamma production in the AML bone marrow microenvironment correlate with patient response to immunotherapeutic agents, including novel bi-specific antibodies. Cutting-edge technologies, such as spatially-resolved highly multiplex digital immunohistochemistry, are being used to analyse the location, density and functional orientation of the different immune cell populations in AML biopsies, i.e., the ‘immune contexture’ of the tumour microenvironment. We are also focusing on the role played by IFN-stimulated genes in mediating resistance of AML cells to chemotherapy agents.

Analysis of high-dimensional transcriptomic data from human tumours.

We have obtained multiple data sets for AML, ovarian, prostate, lung and colorectal cancers from public repositories such as Array Express, TCGA and GEO. Inclusion in these studies is based on sample numbers (n>100) and good clinical annotation of samples (>95% complete coverage for 5 or more clinical features). Each data set is currently being mined for multiple immunological related features. The group has expertise in the identification of molecular features based on artificial neural network (ANN) analysis. We are also using analytical tools (CIBERSORT; PRECOG) to infer the frequency and quality of tumour-infiltrating immune cells from transcriptomic datasets and to identify immune determinants of patient response to therapy.

Pharmacological re-activation of mutant TP53 in acute myeloid leukaemia and its effect on the expression of inflammatory mediators.

TP53-mutated human malignancies, including AML, are characterised by chemotherapy resistance and a poor clinical outcome. The great majority of TP53 mutations in AML are associated with loss-of-function (LOF) of the mutated protein. The team have generated data showing that TP53 mutations correlate with the expression of inflammatory molecules in the tumour microenvironment. This element of work aims to understand how the pharmacological re-activation of TP53 affects the expression of inflammatory genes in AML cells, with a focus on interferon-inducible molecules and immune checkpoints. We use state-of-the-art gene expression profiling and proteomics platforms, as well as conventional cellular and molecular immunology techniques, to interrogate the immune transcriptome and proteome of AML cells bearing TP53 mutations, also dissecting the interplay between TP53 and STAT1, a key interferon-stimulated gene. The following link provides media coverage (2019 SITC Annual Meeting, National Harbor, MD, USA):

Opportunities to carry out postgraduate research towards an MPhil/PhD exist within the School of Science and Technology and further information may be obtained from the NTU Doctoral School.

External activity

Scientific advisory boards; Reviewer of research grants and personal fellowship schemes

2021-Ministry of Health, Singapore (Clinician Scientist - Individual Research Grant Scheme)

2021-Medical Research Council, UK (Clinical Academic Research Partnerships Scheme)

2021-Scientific Advisory Board, Collaborative Research Centre Programme, Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany

2020-Selection Committee, Gottfried Wilhelm Leibniz Prize, Deutsche Forschungsgemeinschaft (DFG), Germany

2020-National Institute for Health Research (NIHR), UK

2020-Innovation and Technology Commission (ITC), Government of Hong Kong

2020-Medical Research Council, UK (New Investigator Research Grant, NIRG; Infections and Immunity Board)

2020-Medical Research Council, UK (Research Grant, Molecular & Cellular Medicine Board)

2020-Irish Cancer Society - Translational Research Fellowship Scheme

2020-Section Editor-In-Chief (Haematology), Journal of Clinical Medicine (IF 5.688)

2019-Fondazione Cariplo, Milan, Italy

2019-King Abdullah International Medical Research Centre (KAIMRC), Saudi Arabia

2019-Prostate Research Cancer Centre, London, United Kingdom

2019-Health and Care Research Wales, United Kingdom

2019-Breast Cancer Now, London, United Kingdom

2019-The Netherlands Organization for Health Research and Development (ZonMw)

2019-Scientific Advisory Board, Institute for Advanced Biosciences (IAB), Grenoble, France

2018-Co-Chair, Clinical & Biomarker Data Sharing Subcommittee, Society for Immunotherapy of Cancer, USA

2018-Medical Research Council/UK Research and Innovation – UKRI Future Leaders Fellowships

2018-Science Foundation Ireland – SFI Career Development Award and Site Review, Dublin

2018-Newton International Fellowships, Academy of Medical Sciences, London, UK

2017-Deputy Chair, Human Ethics Committee, School of Science and Technology, Nottingham Trent University, UK

2017-Scientific Advisory Board, Collaborative Research Centre Programme, Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany

2017-Sparkathon Fellowship (, Society for Immunotherapy of Cancer (SITC), USA

2017-Biomedicines Travel Award, Selection Committee Member, MDPI Publisher, Basel, Switzerland

2016-2018-Institutional Review Board; Alternate Member; Sidra Medical & Research Centre, Doha, Qatar

2016-North West Cancer Research, UK

2016-Genentech Basic Fellowship, Society for Immunotherapy of Cancer (SITC), Bethesda, MD, USA

2015-European Research Council (ERC) Starting Grants, Brussels

2014-Member, Biomarkers Task Force (WG3), Society for the Immunotherapy of Cancer (SITC), USA

2014-STRATEGMED Program, National Centre for Research and Development, Warsaw, Poland

2014-The Danish Council for Independent Research | Medical Sciences, Denmark

2013-Association for International Cancer Research (AICR), Scotland, United Kingdom

2013-Leukaemia & Lymphoma Research (LLR), United Kingdom

2013-French National Research Agency (ANR), Programme de Recherche Translationnelle en Santè (PRTS)

2012-The Netherlands Organization for Health Research and Development (ZonMw)

2012-Dutch Cancer Society, Amsterdam, The Netherlands

2011-San Raffaele University, Milan, Italy

2011-Young Researcher schemes (FIRB), Ministry of Education, University and Research, Italy

2010-Post-doctoral fellowships; Lise Meitner Program, Austrian Science Fund (FWF)

2010-Research Grants Council (RGC), Hong Kong

Media Coverage

Professor Rutella has appeared in several newspaper/media articles. To read the stories, please follow the links below.

  • December 2020            
  • October 2020                
  • September 2020           
  • June 2020                     
  • June 2020                     
  • June 2020                     
  • June 2020                     
  • June 2020                     ,-more-accurate-therapies-for-hard-to-treat-leukaemia-patients
  • May 2020                      
  • April 2020                      
  • April 2020                      
  • January 2020                
  • November 2019            
  • November 2019            
  • November 2019            
  • September 2019           
  • July 2019                                NTU Press Release;
  • April 2019                                Vice Chancellor April Video;
  • January 2019                          BBC East Midlands Today (
  • December 2018            
  • November 2018            
  • November 2018                      NTU News (
  • February 2018                        FHP Living:
  • February 2018                        Haematology News:
  • January 2018                          AML Global Portal:
  • January 2018                          East Midlands Institute of Directors;
  • December 2017                      Q&A with Dr Sergio Rutella: Multi-Analyte studies in acute myeloid leukaemia (
  • December 2017            
  • December 2017                      Nottingham Trent University Donor Report 2017;

Sponsors and collaborators

Current research is being conducted with the collaboration of:

  • John F. DiPersio, MD PhD, Professor and Director, Centre for Gene and Cellular Immunotherapy (CGCI), Washington University School of Medicine, St. Louis, MO, USA
  • Leo Luznik, MD, Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
  • Ivana Gojo, MD, Co-Director, Leukemia Drug Development Program, Associate Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
  • Jan K. Davidson-Moncada, MD PhD, Chief Medical Officer, Wugen, St. Louis, MO, USA
  • Sarah K. Tasian, MD, Assistant Professor of Pediatrics and PI – Leukaemia Biorepository, Division of Oncology, Children’s Hospital of Philadelphia, USA
  • Marc Schmitz, MD, Professor of Immunology and Head of NCT/UCC Immune Monitoring Unit, Institut für Immunologie, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
  • Martin Bornhäuser, MD, Professor of Haematology/Oncology, Co-Head of Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
  • Barbara Seliger, PhD, Professor and Department Chair, Institute for Medical Immunology, Martin Luther University, Halle-Wittenberg, Germany
  • Alessandra Cesano, MD PhD, Chief Medical Officer, ESSA Pharma Inc., South San Francisco, USA

Recent research funding:

  • Investigating the cellular content of HSCT donor/graft and patient samples using immune cell profiling, Anthony Nolan Research Institute, London, UK (2020-2021), £22,000 (Co-Lead: Dr Diana Hernandez).
  • Identification of prognostic/predictive immune gene signatures in patients with relapsed/refractory acute myeloid leukaemia receiving flotetuzumab immunotherapy. MacroGenics, Inc., Rockville, United States of America and NanoString Technologies, Inc., Seattle, United States of America
  • Identification of prognostic/predictive immune gene signatures in patients with advanced gastric cancer receiving immunotherapy with pembrolizumab and anti-HER2 antibodies. MacroGenics, Inc., Rockville, United States of America and NanoString Technologies, Inc., Seattle, United States of America
  • Tipifarnib and interferon signalling in acute myeloid leukaemia. Kura Oncology, San Diego, United States of America
  • Immunological profiling of acute myeloid leukaemia, Roger Counter Foundation, Dorset, UK (2016-2019), £116,000
  • PhD Programme (2017-2020): "Implementation of a novel immune gene profiling platform for the generation and analysis of high-dimensional transcriptomic data from human tumours" (co-funded by NanoString Technologies Inc., USA).
  • Microenvironmental targets for restoring anti-tumour immunity in childhood acute leukaemia, Qatar National Research Fund (2016-2020), NPRP8-2297-3-494; $800,160
  • Alterations of A-to-I RNA editing in acute myeloid leukaemia, Italian Ministry of University and Scientific Research (PRIN; 2012-2014), PRIN-2012; #2012NA9E9Y_004, €374,413
  • Human mesenchymal stromal cells: Optimization of GMP-grade in vitro protocols as a pre-requisite for clinical application, Regione Lazio, Dipartimento Economico e Occupazionale (Lazio Region, Department of Economy and Occupation) (2013-2014), €410,000
  • Molecular determinants of immune dysfunction in childhood leukaemia, Bambino Gesú Children’s Hospital (2012-2013), €100,000
  • Mechanisms underpinning immune tolerance in human tumours and identification of novel strategies to restore immune surveillance, Italian Ministry of University and Scientific Research (PRIN; 2011-2013), PRIN-2009; #2009XMZPKW_002, €273,080
  • Hepatocyte growth factor and immune dysfunction in multiple myeloma, Italian Association for Cancer Research (2009-2012; IG-8556), €150,000


Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis LC, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Recher C, Stiff PJ, Pettit KM, Löwenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida MT, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood 2021; 137 (6): 751–762. DOI: 10.1182/blood.2020007732.

  1. Commentary authored by Gill S: DARTs point the way forward in AML. Blood 2021; 137 (6): 720–721.
  2. Covered by a Blood Podcast (, 11 February 2021

Cesano A, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karanikas V, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Thorsson V, Tschernia N, Wang E, Wells D, Wyant TL, Rutella S. The Society for Immunotherapy of Cancer biomarkers resource document: clinical biomarkers and data sharing Volume II - Practical challenges. Journal for Immunotherapy of Cancer 2020 Dec; 8 (2): e001472. DOI: 10.1136/jitc-2020-001472.

Rutella S, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karanikas V, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Thorsson V, Tschernia N, Wang E, Wells D, Wyant TL, Cesano A. The Society for Immunotherapy of Cancer biomarkers resource document: clinical biomarkers and data sharing Volume I - Conceptual challenges. Journal for Immunotherapy of Cancer 2020 Oct; 8 (2): e001389. DOI: 10.1136/jitc-2020-001389.

*Lai C, *Vadakekolathu J (*=equal contributors), Reeder S, Church SE, Hood T, Lourdusamy A, Rettig MP, Aldoss I, Advani AS, Godwin J, Wieduwilt MJ, Arellano M, Muth J, Yau TO, Ravandi F, Sweet K, Altmann H, Foulds GA, Stölzel F, Middeke JM, Ciciarello M, Curti A, Valk PJM, Löwenberg B, Gojo I, Bornhäuser M, DiPersio JF, Davidson-Moncada JK, Rutella STP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in acute myeloid leukemia. Blood Advances 2020; 4 (20): 5011-24.

Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan A, Viboch E, Patel T, Ibrahimova N, Warren SE, Arruda A, Liang Y, Smith TH, Foulds GA, Bailey MD, Gowen-MacDonald J, Muth J, Schmitz M, Cesano A, Pockley AG, Valk PJM, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JL, DiPersio JF, Rutella S. Immune landscapes predict therapeutic resistance, immunotherapy response and clinical outcomes in acute myeloid leukemia. Science Translational Medicine 2020; 12 (Issue 546): eaaz0463. DOI: 10.1126/scitranslmed.aaz0463

This study was covered by a Diffusion Article published by The Hematologist ("Does the Immune System Matter in Treatment for AML?"), ASH News and Reports, and authored by Drs Jacqueline Taylor and Steven Lane. Please follow the link to the article and listen to an American Society of Hematology podcast where Dr Lane and Professor Rutella discuss the role of the immune system in the treatment of acute myeloid leukaemia (

Flotetuzumab, an investigational CD123×CD3 bispecific Dart® protein, in salvage therapy for primary refractory and early relapsed acute myeloid leukemia (AML) patients. Uy GL, Aldoss I, Foster MC, Sallman DA, Sweet KL, Rizzieri DA, Sayre PH, Advani AS, Emadi A, Wieduwilt MJ, Vey N, Ciceri F, Carrabba MG, Moyo T, Church SE, Rettig MP, Arellano ML, Godwin JE, Löwenberg B, Huls G, Ravandi F, Muth J, Tran K, Jongen-Lavrencic M, Timmeny E, Topp MS, Paolini S, Guo K, Curtis T, Zhao J, Vadakekolathu J, Wigginton JM, Bonvini E, Rutella S, Walter RB, Davidson-Moncada JK, DiPersio JF. Blood 2019; 134 (Supplement_1): 733.

Immune landscapes predict chemotherapy resistance and anti-leukemic activity of flotetuzumab, an investigational CD123×CD3 bispecific Dart® molecule, in patients with relapsed/refractory acute myeloid leukemia. Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Schmitz M, Liang Y, Cesano A, Pockley AG, Valk P, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JK, DiPersio JF, Rutella SBlood 2019; 134 (Supplement_1): 460.

Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study. Rutella S, Vadakekolathu J, Reeder S, Ashforth J, Courtney M, Coutts A, Hood T, Church S, Coveney C, Davidson-Moncada J, Meinel J, Schmitz M, Marincola FM, Bornhäuser M. Journal for Immunotherapy of Cancer 2019; 7 (Supplement_1): O3.

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornhäuser M, Pockley AG, Ball GR, Rutella S. Blood Advances 2019 Apr 23;3(8):1330-1346. doi: 10.1182/bloodadvances.2018030726.

Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Uy GL, Rettig MP, Vey N, Godwin J, Foster MC, Rizzieri DA, Arellano ML, Topp MS, Huls G, Jongen-Lavrencic M, Martinelli G, Paolini S, Ciceri F, Carrabba MG, Sweet KL, Ravandi, Church SE, Vadakekolathu J, Rutella S, Sun J, Yang K, Baughman J, Curtis T, Timmeny E, Cali K, Tran K, Muth J, La Motte-Mohs R, Poirot C, Pallis A, Cesano A, Bonvini E, Wigginton J, Lowenberg B, Davidson-Moncada JK, DiPersio J.F. Blood 2018 132:764.

Adaptive immune gene signatures correlate with response to flotetuzumab, a CD123×CD3 bispecific DART® molecule, in patients with relapsed/refractory acute myeloid leukemia. Rutella S, Church SE, Vadakekolathu J, Viboch E, Sullivan AH, Hood T, Warren SE, Cesano A, LaMotte-Mohs R, Muth J, Lelievre H, Löwenberg B, DiPersio JF, Davidson-Moncada JK. Blood 2018; 132: 444.

Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Katka Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK. Cell Reports 2018 Jun 26;23(13):3946-3959.e6. 10.1016/j.celrep.2018.05.082.

Perspective and Commentary (“Neutrophils take a different tack”) published in Science 2018; 361 (6400): 376-7. DOI: 10.1126/science.361.6400.376-f.

Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology. Rutella S, Vadakekolathu J, Patel T, Reeder S, Schmitz M, Schaarschmidt H, Warren SE, Liang Y, Hood T, Danaher P, Cesano A, Beechem JM, Pockley AG, Tasian SK, Bornhäuser M. Journal of Clinical Oncology 2018; 36 (Suppl. 5S; A#50). 10.1200/JCO.2018.36.5_suppl.50.

Systematic evaluation of immune regulation and modulation. Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B. Journal for Immunotherapy of Cancer 2017 Mar 21;5:21. 10.1186/s40425-017-0223-8.

Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Sala E, Genua M, Petti L, Anselmo A, Arena V, Cibella J, Zanotti L, D’Alessio S, Scaldaferri F, Luca G, Arato I, Calafiore R, Sgambato A, Rutella S, Locati M, Danese S and Vetrano S, Gastroenterology 2015 Jul;149(1):163-176.e20. 10.1053/j.gastro.2015.03.013.

The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. Genua M, D’Alessio S, Cibella J, Gandelli A, Sala E, Correale C, Arena V, Malesci A, Rutella S, Ploplis VA, Vetrano S, and Danese S. Gut 2015 Apr;64(4):589-600. 10.1136/gutjnl-2013-305933.

Kindlin-3-independent adhesion of neutrophils from leukocyte adhesion deficiency type III. van de Vijver E, Tool ATJ, Sanal O, Cetin M, Unal S, Aytac S, Seeger K, Pagliara D, Rutella S, van den Berg TK and Kuijpers TW. Journal of Allergy and Clinical Immunology 2014 Apr;133(4):1215-8. 10.1016/j.jaci.2013.10.020.

HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with non-malignant disorders. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco ME, Handgretinger R, Moretta F, Lucarelli B, Brescia LP, Li Pira G, Testi M, Cancrini C, Kabbara N, Carsetti R, Finocchi A, Moretta A, Moretta L, Locatelli F. Blood 2014, 124 (5), 822-6

Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Peyrin-Biroulet L, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S. Gastroenterology 2013 Feb;144(2):346-356.e3. 10.1053/j.gastro.2012.10.040.

Results of the AIEOP AML 2002/01 multicenter, prospective trial for treatment of children with acute myeloid leukemia. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, and Locatelli F. Blood 2013 Jul 11;122(2):170-8. 10.1182/blood-2013-03-491621.

Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Fagioli F, Quarello P, Zecca M, Lanino E, Rognoni C, Balduzzi A, Messina C, Favre C, Foà R, Ripaldi M, Rutella S, Basso G, Prete A, Locatelli F. Haematologica 2013 Aug;98(8):1273-81. 10.3324/haematol.2012.079707.

How I treat relapsed childhood acute lymphoblastic leukemia. Locatelli F, Schrappe M, Bernardo ME, Rutella S. Blood 2012 Oct 4;120(14):2807-16. 10.1182/blood-2012-02-265884.

Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, Evangelisti C, Rutella S, De Cristofaro R, Ottaviani E, Baccarani M, Lemoli RM. Haematologica 2010 Dec;95(12):2022-30. 10.3324/haematol.2010.025924.

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G. Clinical Cancer Research 2009 Jul 1;15(13):4299-311. 10.1158/1078-0432.CCR-08-1883.

Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R, Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S. Gut 2007 Sep;56(9):1248-56.

Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli I, Horenstein AL, Fiore F, Massaia M, Colombo MP, Baccarani M, Lemoli RM. Blood 2007 Apr 1;109(7):2871-7.

MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Morosetti R, Mirabella M, Gliubizzi C, Broccolini A, De Angelis L, Tagliafico E, Sampaolesi M, Gidaro T, Papacci M, Roncaglia E, Rutella S, Ferrari S, Tonali PA, Ricci E, Cossu G. Proc Natl Acad Sci U S A 2006 Nov 7;103(45):16995-7000.

Tolerogenic dendritic cells: cytokine modulation comes of age. Rutella S, Danese S, Leone G. Blood 2006 Sep 1;108(5):1435-40.

Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F, Di Febo A, Scambia G, Manfredini R, Salati S, Ferrari S, Pierelli L, Leone G, Lemoli RM. Blood 2006 Jul 1;108(1):218-27.

Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F, Lanza GA, Contemi AM, Leone G, Crea F. European Heart Journal 2005 Jun;26(12):1196-204.

Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Voso MT, D'Alo' F, Putzulu R, Mele L, Scardocci A, Chiusolo P, Latagliata R, Lo-Coco F, Rutella S, Pagano L, Hohaus S, Leone G. Blood 2002 Oct 15;100(8):2703-7.

Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d'Onofrio G, Leone G. Blood 2002 Oct 1;100(7):2562-71.

Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Teofili L, Di Febo AL, Pierconti F, Maggiano N, Bendandi M, Rutella S, Cingolani A, Di Renzo N, Musto P, Pileri S, Leone G, Larocca LM. Blood 2001 Feb 15;97(4):1063-9.

Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. Pierelli L, Marone M, Bonanno G, Mozzetti S, Rutella S, Morosetti R, Rumi C, Mancuso S, Leone G, Scambia G. Blood 2000 May 15;95(10):3001-9.

Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. De Stefano V, Teofili L, Sica S, Mastrangelo S, Di Mario A, Rutella S, Salutari P, Rumi C, d'Onofrio G, Leone G. Blood 1995 Nov 1;86(9):3535-41.

Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Testa U, Martucci R, Rutella S, Scambia G, Sica S, Benedetti Panici P, Pierelli L, Menichella G, Leone G, Mancuso S, et al. Blood 1994 Nov 15;84(10):3532-9.

See all of Sergio Rutella's publications...

Press expertise

  • Haematological cancers
  • Leukaemia
  • Immunotherapy (harnessing the immune system to fight cancer)
  • Personalised cancer medicine
  • Cancer genomics